Abbott Laboratories (NYSE:ABT) Stock Gets Price Target Trim from JPMorgan Chase & Co.

Abbott Laboratories (NYSE:ABT) had its price objective cut by JPMorgan Chase & Co. from $120.00 to $118.00 in a report issued on Thursday morning,Benzinga reports. They currently have an overweight rating on the healthcare product maker’s stock.

Several other equities research analysts have also recently issued reports on ABT. Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price for the company in a research note on Thursday, August 13th. Wells Fargo & Company increased their price target on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Barclays began coverage on Abbott Laboratories in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 target price on the stock. TD Cowen dropped their price objective on Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $118.32.

Abbott Laboratories Stock Up 1.2%

Shares of Abbott Laboratories stock opened at $103.70 on Thursday. The company has a market cap of $179.45 billion, a P/E ratio of 38.70, a P/E/G ratio of 1.92 and a beta of 0.59. The stock has a 50-day moving average price of $105.15 and a 200 day moving average price of $98.32. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting the consensus estimate of $1.42. The business had revenue of $13.01 billion during the quarter, compared to analysts’ expectations of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The business’s revenue was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.30 EPS. As a group, analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is 94.03%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC boosted its stake in shares of Abbott Laboratories by 14.1% during the third quarter. Farther Finance Advisors LLC now owns 84,377 shares of the healthcare product maker’s stock valued at $8,339,000 after acquiring an additional 10,431 shares during the last quarter. Juncture Wealth Strategies LLC bought a new position in shares of Abbott Laboratories in the third quarter valued at approximately $658,000. Aureus Asset Management LLC lifted its position in Abbott Laboratories by 25.0% in the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock valued at $34,078,000 after purchasing an additional 66,422 shares during the last quarter. Thompson Investment Management Inc. raised its stake in Abbott Laboratories by 786.0% during the second quarter. Thompson Investment Management Inc. now owns 14,061 shares of the healthcare product maker’s stock valued at $1,276,000 after purchasing an additional 12,474 shares in the last quarter. Finally, Clear Harbor Asset Management LLC acquired a new position in shares of Abbott Laboratories in the 2nd quarter valued at $4,889,000. 75.18% of the stock is currently owned by institutional investors.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.